Recent studies show that ductal carcinoma in situ (DCIS) accompanying HER2+ breast cancer can be completely eradicated following neoadjuvant systemic therapy in up to 52 %. This evidence concerns the gene ERBB2 and ductal breast carcinoma in situ.